Ionis Pharmaceuticals and Genuity Science have partnered on the discovery of up to 20 novel targets rooted in the underlying biology of a range of diseases.
“I’m convinced that the way Genuity Science is working is the future of genomic research.”
Hear from Leo Saheljio, MD, VP of Translational Medicine on the announcement of the collaboration, and why Ionis chose Genuity Science as a partner for this work.Watch Now
Target and Drug Discovery
Based on the causal biology of disease
Validate programs and focus investment
Optimize for success and patient benefit
Identify rapid progressors and severity subtypes for patient stratification
Using pathbreaking single-cell biology and machine learning we elucidated the role of endothelial TGFß signaling in driving vascular inflammation and atherosclerosis, pointing to a major new approach for slowing and even reversing, atherosclerosis and validating it in vivo.
Our AI/ML team employed a proprietary methodology for phenotype projection, determining a causal gene network underpinning vascular pathologies in hypertension and renal dysfunction that can be detected through digital imaging.
Our world-leading genomics platform facilitates fast and easy querying of the UKBB sequence and phenotype data to drive insights from the dataset – enabling us to help you to answer key questions across the drug development process.